Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$226 Mln
P/E Ratio
--
P/B Ratio
30.28
Industry P/E
--
Debt to Equity
-0.31
ROE
-8.51 %
ROCE
-851.67 %
Div. Yield
0 %
Book Value
--
EPS
-1.26
CFO
$-352.98 Mln
EBITDA
$-524.57 Mln
Net Profit
$-163.17 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Humacyte (HUMA)
| -71.68 | -27.04 | -69.05 | -64.16 | -42.24 | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Humacyte (HUMA)
| 76.98 | 34.60 | -70.90 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple... therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. Address: 2525 East North Carolina Highway 54, Durham, NC, United States, 27713 Read more
Founder, President, CEO & Director
Dr. Laura E. Niklason M.D., Ph.D.
Founder, President, CEO & Director
Dr. Laura E. Niklason M.D., Ph.D.
Headquarters
Durham, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Humacyte Inc (HUMA) stood at $ 138 Mln as on 31-Dec-24
The share price of Humacyte Inc (HUMA) is $1.43 (NASDAQ) as of 29-Apr-2025 16:13 EDT. Humacyte Inc (HUMA) has given a return of -42.24% in the last 3 years.
Humacyte Inc (HUMA) has a market capitalisation of $ 226 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Humacyte Inc (HUMA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Humacyte Inc (HUMA) and enter the required number of quantities and click on buy to purchase the shares of Humacyte Inc (HUMA).
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. Address: 2525 East North Carolina Highway 54, Durham, NC, United States, 27713
The CEO & director of Dr. Laura E. Niklason M.D., Ph.D.. is Humacyte Inc (HUMA), and CFO & Sr. VP is Dr. Laura E. Niklason M.D., Ph.D..
There is no promoter pledging in Humacyte Inc (HUMA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Humacyte Inc. (HUMA) | Ratios |
|---|---|
|
Return on equity(%)
|
760.17
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Humacyte Inc (HUMA) was $0 Mln.
$-0.03
(
